Atea Pharmaceuticals (AVIR) Income Statement: Revenue & Earnings

Atea Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Atea Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	351.37	48.63
Cost of Revenue	83.37	70.61	62.39	167.21	38.02
Gross Profit	-83.37	-70.61	-62.39	184.16	10.61
Operating Expenses
Research & Development	145.40	114.24	81.94	167.21	38.02
Selling, General & Administrative	48.85	49.92	48.71	45.79	21.64
Operating Expenses	48.85	164.16	130.65	45.79	21.64
Operating Income	-132.22	-164.16	-130.65	138.38	-11.03
Other Income/Expense
Interest Income	25.49	29.22	11.15	0.21	0.08
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	25.49	0.00	0.00	0.00	-0.54
Income
Income Before Tax	-167.46	-134.94	-119.50	138.59	-10.95
Income Tax Expense	0.93	1.02	-3.59	17.40	0.00
Net Income	-168.39	-135.96	-115.91	121.19	-10.95
Net Income - Continuous Operations	-168.39	-135.96	-115.91	121.19	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-131.80	-134.52	-130.39	138.41	-11.01
EBIT	-132.22	-134.94	-130.65	138.38	-11.03
Depreciation & Amortization	0.42	0.42	0.26	0.03	0.02
Earnings Per Share
Basic EPS	-2.00	-2.00	-1.00	1.00	-1.00
Diluted EPS	-2.00	-2.00	-1.00	1.00	-1.00
Basic Shares Outstanding	84.26	83.39	83.25	82.82	21.59
Diluted Shares Outstanding	84.26	83.39	83.25	88.25	21.59